Neurocrine Announces FDA Approval of 80 mg INGREZZA(R) (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)

First and only TD therapy taken as one capsule, once per day; new 80 mg capsule expected to be available for patients within two weeks INBRACE™ program offers patients access to treatment and patient assistance SAN DIEGO, Oct. 5, 2017 -- (Healthcare ... Biopharmaceuticals, Neurology, FDA Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news